Issuer Flash: Nan Shan Life Insurance

Report date: 2026-06-23 Event date: 2026-05-11 Event title: Q1 2026 results under IFRS 17

1. Flash Conclusion

Nan Shan Life Insurance's Q1 2026 reviewed consolidated financial statements are a positive data point, but they do not change the core view in the May 2026 issuer_summary. The issuer remains a large Taiwanese life insurer with investment-grade ratings, meaningful franchise scale, and proven capital-market access, while its credit profile is still constrained by FX and ALM exposure, large insurance liabilities, market-sensitive investment results, and the regulatory-capital transition.

The most useful new evidence is that the first quarter under the 2026 IFRS 17 / IFRS 9 reporting basis did not show a weak presented balance sheet or a continuation of the March monthly-loss signal. Q1 2026 net profit was NT$8.5bn, compared with a restated Q1 2025 net loss of NT$6.0bn, and consolidated equity increased to NT$372.4bn from restated NT$288.6bn at end-2025. The disclosed net worth ratio rose to 7.04% from 5.52% at end-2025 and 6.84% at end-March 2025.

For bondholders, the result should be read as supportive confirmation rather than a clean credit upgrade. The financial result swung from a restated Q1 2025 loss to a Q1 2026 profit, and OCI was strongly positive, but these lines remain exposed to interest rates, equities, credit spreads, FX translation, hedging economics, and accounting classification. The Q1 report also does not provide enough RBC, TW-ICS, Fitch Prism, hedging-cost, ALM, guaranteed-rate, claims, or product-level profitability information to conclude that the FX and capital questions identified in the issuer_summary have been resolved.

2. What Was Announced

Nan Shan Life published its Q1 2026 consolidated financial statements and independent auditors' review report for the period ended March 31, 2026. The report is important because 2026 is the first reporting year in which the company applied IFRS 17 to insurance contracts and adjusted the related IFRS 9 financial-asset classification framework. Comparisons with 2025 therefore need to use the restated figures shown in the report rather than the old presentation.

On the income statement, the insurance service result was stable but not the source of the main improvement. Insurance revenue was NT$30.8bn and insurance service expenses were NT$21.8bn, leaving an insurance service result of NT$8.8bn, slightly below restated Q1 2025 of NT$9.0bn. The more visible change came from the financial result, which was a positive NT$6.5bn in Q1 2026 versus a restated loss of NT$7.6bn in Q1 2025. Pretax profit was NT$9.5bn and net profit was NT$8.5bn, compared with a restated pretax loss of NT$4.8bn and net loss of NT$6.0bn in Q1 2025.

The balance sheet also improved in presentation. Total assets were NT$5,598.4bn at end-March 2026, up from restated NT$5,535.6bn at end-2025. Total liabilities were NT$5,225.9bn, and equity was NT$372.4bn. Insurance contract liabilities remained very large at NT$4,509.4bn, while bonds payable were NT$126.8bn, broadly in line with end-2025 and higher than the restated end-March 2025 level of NT$87.6bn after the 2025 funding actions.

3. Credit Read-Through

The Q1 result is credit-supportive mainly because it reduces near-term concern that the March 2026 monthly loss represented a broader earnings deterioration. A reviewed quarterly report showing NT$8.5bn of net profit, positive financial result, and a stronger equity base is materially better evidence than one volatile monthly self-reported figure. This is consistent with the issuer_summary caution that monthly insurer earnings should not be overinterpreted.

The stronger equity and net worth ratio are also helpful. Moving from a restated 5.52% net worth ratio at end-2025 to 7.04% at end-March 2026 suggests that the first quarter's market and accounting effects improved presented capital. However, the credit meaning should be limited. Net worth ratio is not a substitute for regulatory capital, rating-agency capital models, stress sensitivity, or the economics of the FX reserve. Without updated RBC, TW-ICS or Prism information, the report cannot support a conclusion that capital headroom is now comfortably above stress needs.

The financial-result improvement deserves a cautious reading. Interest income rose, fair-value losses through profit or loss were less negative than in restated Q1 2025, realized gains on FVOCI assets increased, and exchange gains remained large. These items helped the quarter, but they also show why Nan Shan Life's credit remains market-sensitive. Positive quarterly financial income does not eliminate the structural issue identified in the issuer_summary and Fitch commentary: a large foreign-currency investment book, insurance liabilities with long duration, and sensitivity to Taiwan-dollar appreciation, hedging cost, and valuation movements.

The balance sheet still points to life-insurance rather than ordinary corporate credit analysis. Insurance contract liabilities of NT$4.5tn dominate the liability side, and financial assets at amortized cost and FVOCI remain the largest asset categories. Credit analysis therefore needs to stay focused on ALM, currency matching, liquidity under surrender stress, liability assumptions, and regulatory capital rather than on simple leverage. Bonds payable of NT$126.8bn also mean that security-level analysis remains important for Tier 2 and other capital instruments.

4. Key Numbers

Figures are in NT$bn unless stated otherwise. Q1 2025 and end-2025 comparatives are the restated figures shown in the Q1 2026 report.

5. What To Watch Next

The next check should focus on whether this first positive IFRS 17 quarter becomes a durable pattern. The most important items are RBC or TW-ICS metrics, any Fitch Prism update, rating-agency follow-up, net worth ratio trend, FX valuation reserve, hedging cost, USD/TWD sensitivity, and the balance between foreign-currency assets and foreign-currency liabilities.

Operationally, investors should watch whether insurance service result remains stable and whether future quarters provide more detail on CSM, new business quality, claims, surrender behavior, guaranteed rates, and product-level profitability. The Q1 report supports the current investment-grade major-insurer view, but it does not remove the need to monitor FX, ALM, regulatory capital, and security-level subordination before taking a position in individual Nan Shan Life or Nanshan Life Pte. Ltd. instruments.

6. Sources

• Nan Shan Life Insurance Company, Ltd. and subsidiaries, Consolidated Financial Statements and Independent Auditors' Review Report, Q1 2026, public disclosure date 2026-05-11. Used to verify Q1 2026 income statement, balance sheet, OCI, net worth ratio, and IFRS 17 / IFRS 9 transition context.
  https://www.nanshanlife.com.tw/nanshanlife/portal-api/File/11162
• issuer_report_management/disclosure_search/issuers/nan_shan_life_insurance.json, used to confirm the public disclosure date, document type, period end, source URL, and next-search metadata.
• issuer_summary/issuers/nan_shan_life_insurance/current/nan_shan_life_insurance_issuer_summary_20260514.md, used for the existing credit view, monitoring focus, and issuer-specific cautions.
• issuer_summary/issuers/nan_shan_life_insurance/issuer_notes.md, knowledge_snapshot.md, and source_registry.md, used for issuer memory, continuing source routes, and unresolved monitoring items.